New Molecular Ecosystem Revolutionizes Classification and Treatment of Aggressive Chronic Myelomonocytic Leukemia for Older Adults

New molecular ecosystem for CMML classifies patients into nine distinct groups, extending survival by optimizing the timing of stem cell transplants.

By: AXL Media

Published: Apr 30, 2026, 8:06 AM EDT

Source: Information for this report was sourced from EurekAlert!

Bridging the Diagnostic Gap in Myeloid Disease Management

Chronic myelomonocytic leukemia, or CMML, has long occupied a difficult biological space between myeloproliferative and myelodysplastic diseases, leading to significant diagnostic confusion. For over two decades, clinicians have struggled to predict which patients will remain stable and which will face a rapid transformation into acute myeloid leukemia. A landmark study published in the Journal of Clinical Oncology now introduces a comprehensive molecular ecosystem designed to address this unpredictability. By combining a novel classification system with AI-assisted decision support, researchers aim to provide a more precise roadmap for managing this rare and aggressive blood cancer, which primarily affects older populations.

Decoding the Genomic Architecture of Rare Blood Cancers

The international study, involving a consortium known as the iCPSS Alliance, utilized an extensive dataset of over 3,500 patients to map the genetic drivers of the disease. Using unsupervised clustering across 43 specific genes, the team identified nine biologically and clinically distinct molecular classes. These range from favorable subtypes with survival expectations exceeding eight years to high-risk categories where median survival drops to approximately one year. This new taxonomy moves beyond broad generalizations, allowing doctors to recognize high-risk genetic signatures, such as biallelic TP53 inactivation, much earlier in the disease progression.

Improving Risk Stratification Through the iCPSS Score

Building upon this molecular map, the researchers developed the International CMML Prognostic Scoring System, or iCPSS. This tool integrates mutations in nine key genes with standard hematologic parameters to provide superior prognostic discrimination compared to all existing models. When tested against current standards, the iCPSS re-stratified more than half of the patients involved in the study. Specifically, 35% of patients were downstaged to lower risk groups while 20% were upstaged, proving that previous tools frequently missed critical clinical information that dictates patient outcomes.